Glycine by enteral route does not improve major clinical outcomes in severe COVID-19: a randomized clinical pilot trial

• Published in: Scientific reports Vol. 14; no. 1; pp. 11566 - 10
• Main Authors: Vargas, Mario H., Chávez, Jaime, Del-Razo-Rodríguez, Rosangela, Muñoz-Perea, Carolina, Romo-Domínguez, Karina Julieta, Báez-Saldaña, Renata, Rumbo-Nava, Uriel, Guerrero-Zúñiga, Selene
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 21.05.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 692/308/2779/777; 692/308/53/2422; 692/699/1785/3193; 692/699/255/2514; Aged; Clinical outcomes; COVID-19; COVID-19 - blood; COVID-19 - mortality; COVID-19 - therapy; COVID-19 Drug Treatment; Cytokines; Cytokines - blood; Endothelium; Female; Fibrinogen; Fibrinogen - analysis; Fibrinogen - metabolism; Glycine; Glycine - administration & dosage; Glycine - therapeutic use; Humanities and Social Sciences; Humans; Inflammation; Laboratory tests; Male; Mechanical ventilation; Middle Aged; Mortality; multidisciplinary; NCT; NCT04443673; Pilot Projects; Respiration, Artificial; SARS-CoV-2; Science; Science (multidisciplinary); Treatment Outcome; Ventilation; Weaning

There is a worrying scarcity of drug options for patients with severe COVID-19. Glycine possesses anti-inflammatory, cytoprotective, endothelium-protective, and platelet-antiaggregant properties, so its use in these patients seems promising. In this open label, controlled clinical trial, inpatients...